Woodline Partners’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-69,576
| Closed | -$77.9K | – | 969 |
|
|
2025
Q2 | $77.9K | Hold |
69,576
| – | – | ﹤0.01% | 909 |
|
|
2025
Q1 | $80K | Buy |
69,576
+2,317
| +3% | +$4.31K | ﹤0.01% | 888 |
|
|
2024
Q4 | $411K | Hold |
67,259
| – | – | ﹤0.01% | 859 |
|
|
2024
Q3 | $1.11M | Sell |
67,259
-7,741
| -10% | -$84.8K | 0.01% | 504 |
|
|
2024
Q2 | $515K | Hold |
75,000
| – | – | ﹤0.01% | 499 |
|
|
2024
Q1 | $724K | Hold |
75,000
| – | – | 0.01% | 463 |
|
|
2023
Q4 | $623K | Hold |
75,000
| – | – | 0.01% | 419 |
|
|
2023
Q3 | $626K | Hold |
75,000
| – | – | 0.01% | 481 |
|
|
2023
Q2 | $692K | Sell |
75,000
-78,825
| -51% | -$883K | 0.01% | 515 |
|
|
2023
Q1 | $2.11M | Buy |
153,825
+3,825
| +3% | +$79.1K | 0.03% | 409 |
|
|
2022
Q4 | $2.55M | Sell |
150,000
-50,047
| -25% | -$1M | 0.03% | 440 |
|
|
2022
Q3 | $4.55M | Hold |
200,047
| – | – | 0.06% | 311 |
|
|
2022
Q2 | $3.61M | Sell |
200,047
-203,354
| -50% | -$3.62M | 0.06% | 308 |
|
|
2022
Q1 | $10.8M | Hold |
403,401
| – | – | 0.18% | 167 |
|
|
2021
Q4 | $11.8M | Sell |
403,401
-165,608
| -29% | -$8.23M | 0.17% | 163 |
|
|
2021
Q3 | $37.4M | Sell |
569,009
-176,384
| -24% | -$13.5M | 0.61% | 36 |
|
|
2021
Q2 | $62M | Buy |
745,393
+314,710
| +73% | +$23.3M | 1.16% | 15 |
|
|
2021
Q1 | $33M | Sell |
430,683
-109,733
| -20% | -$9.99M | 0.73% | 37 |
|
|
2020
Q4 | $47.7M | Buy |
540,416
+450,038
| +498% | +$31.6M | 1.27% | 19 |
|
|
2020
Q3 | $6.67M | Buy |
+90,378
| New | +$5.35M | 0.22% | 109 |
|
Other funds holding IGMS
Woodline Partners's IGMS Position: Q3 2025 in Review
Woodline Partners sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 69,576 shares — an estimated $77.9K sold.
Woodline Partners first reported a position in IGMS in Q3 2020 and held it in 20 quarters. The position peaked at $62M in Q2 2021. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- Woodline Partners reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- Woodline Partners sold 69,576 IGM Biosciences shares in Q3 2025, an estimated $77.9K.
- Woodline Partners first reported a position in IGM Biosciences in Q3 2020 and held it in 20 quarters.
- Woodline Partners's IGM Biosciences position peaked at $62M in Q2 2021.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.